As of Nov 22
| +0.07 / +1.46%|
The 7 analysts offering 12-month price forecasts for Keryx Biopharmaceuticals Inc have a median target of 7.00, with a high estimate of 9.00 and a low estimate of 5.00. The median estimate represents a +43.74% increase from the last price of 4.87.
The current consensus among 8 polled investment analysts is to Hold stock in Keryx Biopharmaceuticals Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.